AstraZeneca (AZN) Receives “Overweight” Rating from Barclays
A number of other brokerages have also recently issued reports on AZN. Liberum Capital restated a hold rating on shares of AstraZeneca in a report on Friday, March 29th. Jefferies Financial Group restated a hold rating on shares of AstraZeneca in a report on Thursday, March 14th. Goldman Sachs Group restated a sell rating on shares of AstraZeneca in a report on Monday, March 18th. Deutsche Bank restated a buy rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Tuesday, February 26th. Finally, Shore Capital restated a buy rating on shares of AstraZeneca in a report on Friday, March 29th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of GBX 6,362.70 ($83.14).
AstraZeneca stock traded down GBX 115 ($1.50) during midday trading on Wednesday, reaching GBX 6,005 ($78.47). 953,300 shares of the company’s stock were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 52 week low of GBX 4,850 ($63.37) and a 52 week high of GBX 6,540 ($85.46). The company has a debt-to-equity ratio of 136.31, a quick ratio of 0.71 and a current ratio of 0.96. The stock has a market capitalization of $79.57 billion and a P/E ratio of 35.32.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: What are the FAANG Stocks?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.